| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 4 | 2025 | 131 | 1.860 |
Why?
|
| Papillomavirus Infections | 4 | 2025 | 142 | 1.860 |
Why?
|
| United States Department of Veterans Affairs | 14 | 2022 | 127 | 1.490 |
Why?
|
| Delivery of Health Care | 8 | 2022 | 390 | 1.380 |
Why?
|
| Quality of Health Care | 13 | 2022 | 259 | 1.300 |
Why?
|
| Health Services Research | 8 | 2021 | 202 | 1.250 |
Why?
|
| Translational Medical Research | 7 | 2020 | 33 | 1.190 |
Why?
|
| Humans | 96 | 2025 | 17314 | 1.170 |
Why?
|
| Evidence-Based Practice | 6 | 2022 | 55 | 1.150 |
Why?
|
| Early Detection of Cancer | 5 | 2025 | 529 | 1.060 |
Why?
|
| Practice Patterns, Physicians' | 12 | 2020 | 302 | 1.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 8 | 2024 | 367 | 0.970 |
Why?
|
| Mass Screening | 4 | 2025 | 672 | 0.950 |
Why?
|
| Quality Improvement | 6 | 2017 | 188 | 0.940 |
Why?
|
| Periodicals as Topic | 3 | 2020 | 14 | 0.900 |
Why?
|
| Diffusion of Innovation | 5 | 2017 | 35 | 0.890 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2022 | 184 | 0.860 |
Why?
|
| Kidney Transplantation | 2 | 2022 | 30 | 0.830 |
Why?
|
| Editorial Policies | 2 | 2012 | 5 | 0.740 |
Why?
|
| Patient Education as Topic | 6 | 2020 | 193 | 0.740 |
Why?
|
| Hospitals, Veterans | 3 | 2014 | 31 | 0.730 |
Why?
|
| United States | 34 | 2022 | 3866 | 0.720 |
Why?
|
| Information Dissemination | 7 | 2020 | 50 | 0.700 |
Why?
|
| Parkinson Disease | 4 | 2022 | 15 | 0.650 |
Why?
|
| Primary Health Care | 10 | 2025 | 726 | 0.650 |
Why?
|
| Continuity of Patient Care | 6 | 2020 | 103 | 0.630 |
Why?
|
| Female | 46 | 2025 | 12396 | 0.590 |
Why?
|
| Stroke | 5 | 2025 | 309 | 0.570 |
Why?
|
| Attitude of Health Personnel | 7 | 2020 | 197 | 0.540 |
Why?
|
| Capacity Building | 2 | 2015 | 11 | 0.520 |
Why?
|
| Smoking Cessation | 3 | 2008 | 154 | 0.510 |
Why?
|
| Evidence-Based Medicine | 9 | 2018 | 169 | 0.510 |
Why?
|
| Mental Health Services | 3 | 2020 | 155 | 0.490 |
Why?
|
| Ischemic Attack, Transient | 3 | 2021 | 27 | 0.470 |
Why?
|
| Risk Reduction Behavior | 5 | 2021 | 104 | 0.470 |
Why?
|
| Community Health Services | 5 | 2022 | 79 | 0.470 |
Why?
|
| Personnel, Hospital | 1 | 2014 | 9 | 0.460 |
Why?
|
| Chiropractic | 1 | 2014 | 9 | 0.460 |
Why?
|
| Health Promotion | 6 | 2022 | 279 | 0.450 |
Why?
|
| Middle Aged | 31 | 2025 | 7836 | 0.450 |
Why?
|
| Safety-net Providers | 4 | 2025 | 55 | 0.430 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2022 | 312 | 0.430 |
Why?
|
| Delivery of Health Care, Integrated | 5 | 2022 | 535 | 0.420 |
Why?
|
| Biomedical Research | 2 | 2020 | 76 | 0.420 |
Why?
|
| Aged | 29 | 2025 | 6084 | 0.420 |
Why?
|
| Male | 37 | 2025 | 9804 | 0.420 |
Why?
|
| Research Design | 7 | 2021 | 336 | 0.410 |
Why?
|
| Referral and Consultation | 4 | 2020 | 157 | 0.400 |
Why?
|
| Education, Medical, Graduate | 1 | 2013 | 17 | 0.400 |
Why?
|
| Schools, Medical | 1 | 2013 | 15 | 0.400 |
Why?
|
| California | 14 | 2025 | 2311 | 0.390 |
Why?
|
| Patient-Centered Care | 4 | 2020 | 186 | 0.380 |
Why?
|
| Interviews as Topic | 6 | 2020 | 306 | 0.380 |
Why?
|
| Decision Making | 4 | 2020 | 171 | 0.370 |
Why?
|
| Guidelines as Topic | 4 | 2014 | 41 | 0.370 |
Why?
|
| Alzheimer Disease | 2 | 2002 | 49 | 0.360 |
Why?
|
| Ethics Committees, Research | 1 | 2011 | 9 | 0.350 |
Why?
|
| Research Personnel | 4 | 2020 | 28 | 0.350 |
Why?
|
| Self-Management | 2 | 2021 | 24 | 0.340 |
Why?
|
| Outcome Assessment (Health Care) | 5 | 2017 | 215 | 0.330 |
Why?
|
| Cooperative Behavior | 4 | 2020 | 89 | 0.310 |
Why?
|
| Academies and Institutes | 3 | 2020 | 7 | 0.310 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2007 | 22 | 0.310 |
Why?
|
| Patient Outcome Assessment | 2 | 2020 | 28 | 0.300 |
Why?
|
| Practice Guidelines as Topic | 8 | 2008 | 310 | 0.300 |
Why?
|
| Electronic Health Records | 4 | 2022 | 704 | 0.300 |
Why?
|
| Health Policy | 3 | 2015 | 109 | 0.290 |
Why?
|
| Papillomaviridae | 2 | 2025 | 61 | 0.280 |
Why?
|
| Transitional Care | 3 | 2017 | 19 | 0.280 |
Why?
|
| Adult | 19 | 2025 | 7500 | 0.280 |
Why?
|
| Patient Discharge | 4 | 2017 | 153 | 0.280 |
Why?
|
| Exercise Therapy | 2 | 2020 | 72 | 0.270 |
Why?
|
| Total Quality Management | 4 | 2004 | 18 | 0.270 |
Why?
|
| HIV Infections | 3 | 2020 | 712 | 0.260 |
Why?
|
| Guideline Adherence | 3 | 2007 | 149 | 0.260 |
Why?
|
| Clinical Protocols | 2 | 2017 | 40 | 0.250 |
Why?
|
| Patient Readmission | 3 | 2017 | 161 | 0.250 |
Why?
|
| Specialization | 3 | 2007 | 21 | 0.250 |
Why?
|
| Surveys and Questionnaires | 11 | 2024 | 1282 | 0.250 |
Why?
|
| Pragmatic Clinical Trials as Topic | 2 | 2025 | 61 | 0.250 |
Why?
|
| Dementia | 4 | 2011 | 121 | 0.240 |
Why?
|
| Ambulatory Care Facilities | 1 | 2006 | 64 | 0.240 |
Why?
|
| Nervous System Diseases | 3 | 2004 | 19 | 0.240 |
Why?
|
| Terminal Care | 1 | 2025 | 45 | 0.230 |
Why?
|
| Palliative Care | 1 | 2025 | 52 | 0.220 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 437 | 0.220 |
Why?
|
| Veterans | 3 | 2020 | 145 | 0.220 |
Why?
|
| Heart Failure | 2 | 2022 | 401 | 0.210 |
Why?
|
| Medicine | 2 | 2007 | 18 | 0.210 |
Why?
|
| Hypertension | 2 | 2021 | 469 | 0.210 |
Why?
|
| Cost-Benefit Analysis | 4 | 2019 | 226 | 0.210 |
Why?
|
| Curriculum | 2 | 2013 | 36 | 0.200 |
Why?
|
| Los Angeles | 6 | 2025 | 139 | 0.200 |
Why?
|
| Quality Assurance, Health Care | 5 | 2017 | 124 | 0.190 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 532 | 0.190 |
Why?
|
| Outcome and Process Assessment (Health Care) | 5 | 2017 | 97 | 0.190 |
Why?
|
| Indans | 1 | 2002 | 1 | 0.190 |
Why?
|
| Piperidines | 1 | 2002 | 1 | 0.190 |
Why?
|
| Phenylcarbamates | 1 | 2002 | 1 | 0.190 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2002 | 4 | 0.190 |
Why?
|
| Geriatric Assessment | 1 | 2002 | 43 | 0.190 |
Why?
|
| Preventive Health Services | 2 | 2020 | 147 | 0.190 |
Why?
|
| Medicare | 4 | 2017 | 192 | 0.190 |
Why?
|
| Comparative Effectiveness Research | 2 | 2020 | 62 | 0.190 |
Why?
|
| Laboratories | 1 | 2022 | 19 | 0.190 |
Why?
|
| Hyperkalemia | 1 | 2022 | 15 | 0.180 |
Why?
|
| Telemedicine | 1 | 2025 | 181 | 0.180 |
Why?
|
| Information Services | 4 | 2001 | 12 | 0.180 |
Why?
|
| Program Evaluation | 4 | 2018 | 205 | 0.180 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 44 | 0.180 |
Why?
|
| Hip Fractures | 1 | 2022 | 71 | 0.180 |
Why?
|
| Disease Management | 2 | 2015 | 111 | 0.180 |
Why?
|
| Medication Adherence | 2 | 2021 | 235 | 0.180 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 53 | 0.180 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 84 | 0.180 |
Why?
|
| Secondary Prevention | 2 | 2021 | 48 | 0.170 |
Why?
|
| Papillomavirus Vaccines | 1 | 2022 | 114 | 0.170 |
Why?
|
| Quarantine | 1 | 2021 | 10 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 109 | 0.170 |
Why?
|
| Stroke Rehabilitation | 1 | 2020 | 3 | 0.170 |
Why?
|
| Nurses | 1 | 2020 | 33 | 0.170 |
Why?
|
| Quality Indicators, Health Care | 1 | 2022 | 125 | 0.170 |
Why?
|
| Peer Group | 1 | 2001 | 54 | 0.170 |
Why?
|
| Financing, Organized | 1 | 2020 | 5 | 0.170 |
Why?
|
| HIV Long-Term Survivors | 1 | 2020 | 2 | 0.170 |
Why?
|
| Culturally Competent Care | 1 | 2020 | 11 | 0.160 |
Why?
|
| Economics, Behavioral | 1 | 2020 | 4 | 0.160 |
Why?
|
| Organizations | 1 | 2020 | 8 | 0.160 |
Why?
|
| Social Networking | 1 | 2020 | 19 | 0.160 |
Why?
|
| Models, Organizational | 2 | 2015 | 54 | 0.160 |
Why?
|
| Women's Health | 2 | 2020 | 197 | 0.160 |
Why?
|
| House Calls | 1 | 2019 | 11 | 0.160 |
Why?
|
| Hospice and Palliative Care Nursing | 1 | 2019 | 8 | 0.160 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 154 | 0.160 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2020 | 68 | 0.160 |
Why?
|
| Home Care Services | 1 | 2019 | 28 | 0.150 |
Why?
|
| Blood Pressure | 1 | 2021 | 275 | 0.150 |
Why?
|
| Social Support | 1 | 2001 | 207 | 0.150 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 1925 | 0.150 |
Why?
|
| Patient Selection | 1 | 2020 | 176 | 0.150 |
Why?
|
| African Americans | 3 | 2021 | 439 | 0.150 |
Why?
|
| Documentation | 3 | 2016 | 40 | 0.150 |
Why?
|
| Health Care Costs | 2 | 2019 | 207 | 0.150 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 153 | 0.150 |
Why?
|
| Anti-HIV Agents | 1 | 2020 | 159 | 0.150 |
Why?
|
| Interdisciplinary Communication | 2 | 2015 | 18 | 0.150 |
Why?
|
| Sweden | 1 | 2017 | 19 | 0.140 |
Why?
|
| Health Priorities | 2 | 2020 | 24 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 165 | 0.140 |
Why?
|
| Retrospective Studies | 7 | 2022 | 2415 | 0.140 |
Why?
|
| Rheumatology | 2 | 2007 | 3 | 0.130 |
Why?
|
| Communication | 2 | 2015 | 178 | 0.130 |
Why?
|
| Research | 2 | 2016 | 61 | 0.130 |
Why?
|
| Patient Care Management | 2 | 2020 | 25 | 0.130 |
Why?
|
| Cerebral Hemorrhage | 1 | 2017 | 12 | 0.130 |
Why?
|
| Sleep Medicine Specialty | 1 | 2016 | 5 | 0.130 |
Why?
|
| Pulmonary Medicine | 1 | 2016 | 19 | 0.130 |
Why?
|
| HLA-B27 Antigen | 1 | 2016 | 1 | 0.130 |
Why?
|
| Hemochromatosis Protein | 1 | 2016 | 7 | 0.130 |
Why?
|
| Factor V | 1 | 2016 | 5 | 0.130 |
Why?
|
| Hospitals | 1 | 2017 | 71 | 0.130 |
Why?
|
| Organizational Objectives | 2 | 2014 | 14 | 0.130 |
Why?
|
| Caregivers | 3 | 2011 | 128 | 0.120 |
Why?
|
| Critical Care | 1 | 2016 | 66 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2021 | 1160 | 0.120 |
Why?
|
| Genetic Testing | 1 | 2016 | 69 | 0.120 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2015 | 26 | 0.120 |
Why?
|
| Awards and Prizes | 1 | 2015 | 9 | 0.120 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 145 | 0.120 |
Why?
|
| Hospital Administration | 1 | 2015 | 5 | 0.120 |
Why?
|
| Program Development | 1 | 2015 | 63 | 0.120 |
Why?
|
| Health Education | 2 | 2012 | 82 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 1151 | 0.120 |
Why?
|
| Medical History Taking | 2 | 2013 | 33 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2024 | 381 | 0.110 |
Why?
|
| Pilot Projects | 3 | 2020 | 211 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 202 | 0.110 |
Why?
|
| Walking | 1 | 2015 | 89 | 0.110 |
Why?
|
| Sexual Partners | 1 | 2014 | 38 | 0.110 |
Why?
|
| Capitation Fee | 4 | 2000 | 10 | 0.110 |
Why?
|
| Single-Blind Method | 3 | 2021 | 40 | 0.110 |
Why?
|
| General Practice | 1 | 2014 | 6 | 0.110 |
Why?
|
| United States Agency for Healthcare Research and Quality | 2 | 1994 | 10 | 0.110 |
Why?
|
| Self Care | 3 | 2020 | 144 | 0.110 |
Why?
|
| Benchmarking | 3 | 2004 | 36 | 0.100 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2013 | 1 | 0.100 |
Why?
|
| Genetic Services | 1 | 2013 | 2 | 0.100 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2013 | 15 | 0.100 |
Why?
|
| Health Status | 4 | 2020 | 293 | 0.100 |
Why?
|
| Missouri | 1 | 2013 | 9 | 0.100 |
Why?
|
| Neoplasms | 2 | 2012 | 446 | 0.100 |
Why?
|
| Time Factors | 3 | 2020 | 1039 | 0.100 |
Why?
|
| Journal Impact Factor | 1 | 2012 | 2 | 0.100 |
Why?
|
| Risk Factors | 4 | 2022 | 3258 | 0.100 |
Why?
|
| Cross-Sectional Studies | 7 | 2008 | 1280 | 0.090 |
Why?
|
| Pneumonia | 2 | 2003 | 49 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 384 | 0.090 |
Why?
|
| Health Maintenance Organizations | 4 | 1997 | 407 | 0.090 |
Why?
|
| Patient Care Team | 3 | 2021 | 105 | 0.090 |
Why?
|
| Public Health | 1 | 2012 | 83 | 0.090 |
Why?
|
| Physicians | 3 | 2021 | 117 | 0.090 |
Why?
|
| Informed Consent | 1 | 2011 | 19 | 0.090 |
Why?
|
| China | 2 | 2025 | 132 | 0.090 |
Why?
|
| Neurology | 2 | 2004 | 7 | 0.090 |
Why?
|
| Antirheumatic Agents | 2 | 2007 | 11 | 0.080 |
Why?
|
| Health Care Surveys | 3 | 2006 | 211 | 0.080 |
Why?
|
| Disease Progression | 2 | 2019 | 259 | 0.080 |
Why?
|
| Uterine Diseases | 2 | 2000 | 5 | 0.080 |
Why?
|
| Education, Medical, Continuing | 3 | 2020 | 31 | 0.080 |
Why?
|
| Societies, Medical | 3 | 2016 | 71 | 0.080 |
Why?
|
| Hysterectomy | 2 | 2000 | 29 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 969 | 0.070 |
Why?
|
| Minority Groups | 2 | 2022 | 104 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2008 | 67 | 0.070 |
Why?
|
| Joints | 2 | 2007 | 2 | 0.070 |
Why?
|
| Self-Examination | 2 | 2007 | 4 | 0.070 |
Why?
|
| Utilization Review | 2 | 2000 | 42 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2020 | 81 | 0.070 |
Why?
|
| Inservice Training | 2 | 2020 | 14 | 0.070 |
Why?
|
| Memory Disorders | 1 | 2007 | 8 | 0.070 |
Why?
|
| Asian Americans | 2 | 2021 | 163 | 0.070 |
Why?
|
| Personal Health Services | 1 | 2007 | 3 | 0.070 |
Why?
|
| Vaccination | 2 | 2022 | 688 | 0.070 |
Why?
|
| Child | 3 | 2022 | 2403 | 0.060 |
Why?
|
| Community-Acquired Infections | 2 | 2003 | 20 | 0.060 |
Why?
|
| Hispanic Americans | 2 | 2021 | 375 | 0.060 |
Why?
|
| Reimbursement Mechanisms | 2 | 2004 | 17 | 0.060 |
Why?
|
| Health Plan Implementation | 1 | 2006 | 35 | 0.060 |
Why?
|
| Algorithms | 2 | 2004 | 223 | 0.060 |
Why?
|
| Focus Groups | 2 | 2016 | 143 | 0.060 |
Why?
|
| Mobile Applications | 1 | 2025 | 14 | 0.060 |
Why?
|
| Health Personnel | 1 | 2006 | 126 | 0.060 |
Why?
|
| Papanicolaou Test | 1 | 2024 | 37 | 0.060 |
Why?
|
| Comorbidity | 2 | 2007 | 560 | 0.060 |
Why?
|
| Vaginal Smears | 1 | 2024 | 47 | 0.060 |
Why?
|
| Perception | 1 | 2024 | 56 | 0.050 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2004 | 7 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2025 | 99 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2004 | 19 | 0.050 |
Why?
|
| Cohort Studies | 4 | 2016 | 2514 | 0.050 |
Why?
|
| Length of Stay | 3 | 2016 | 171 | 0.050 |
Why?
|
| Malpractice | 1 | 2004 | 12 | 0.050 |
Why?
|
| Quality of Life | 2 | 2015 | 499 | 0.050 |
Why?
|
| Professional-Patient Relations | 2 | 2001 | 48 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 2 | 2003 | 143 | 0.050 |
Why?
|
| Residence Characteristics | 2 | 2016 | 253 | 0.050 |
Why?
|
| Homes for the Aged | 1 | 2003 | 6 | 0.050 |
Why?
|
| Pressure Ulcer | 1 | 2003 | 5 | 0.050 |
Why?
|
| Nursing Homes | 1 | 2003 | 10 | 0.050 |
Why?
|
| Pelvic Pain | 1 | 2002 | 3 | 0.050 |
Why?
|
| Endometriosis | 1 | 2002 | 4 | 0.050 |
Why?
|
| Logistic Models | 2 | 2002 | 879 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 146 | 0.050 |
Why?
|
| Rivastigmine | 1 | 2002 | 1 | 0.050 |
Why?
|
| Risperidone | 1 | 2002 | 2 | 0.050 |
Why?
|
| Lorazepam | 1 | 2002 | 3 | 0.050 |
Why?
|
| Carbamates | 1 | 2002 | 8 | 0.050 |
Why?
|
| Advance Directives | 1 | 2002 | 7 | 0.050 |
Why?
|
| Mood Disorders | 1 | 2002 | 16 | 0.050 |
Why?
|
| Neuropsychological Tests | 1 | 2002 | 43 | 0.050 |
Why?
|
| Family Practice | 1 | 2002 | 40 | 0.050 |
Why?
|
| Cholic Acids | 1 | 2022 | 1 | 0.050 |
Why?
|
| Nurse's Role | 1 | 2022 | 7 | 0.050 |
Why?
|
| Social Class | 1 | 2022 | 116 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2002 | 81 | 0.050 |
Why?
|
| Cats | 1 | 2021 | 8 | 0.050 |
Why?
|
| Fluoxetine | 1 | 2021 | 17 | 0.050 |
Why?
|
| Medical Records | 3 | 2007 | 91 | 0.050 |
Why?
|
| Cognition | 1 | 2002 | 81 | 0.050 |
Why?
|
| Physician Assistants | 1 | 2021 | 7 | 0.040 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2021 | 9 | 0.040 |
Why?
|
| Community Health Workers | 1 | 2021 | 13 | 0.040 |
Why?
|
| Psychology, Social | 1 | 2001 | 2 | 0.040 |
Why?
|
| Prejudice | 1 | 2001 | 22 | 0.040 |
Why?
|
| Nurse Practitioners | 1 | 2021 | 20 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2001 | 21 | 0.040 |
Why?
|
| Psychiatry | 1 | 2001 | 22 | 0.040 |
Why?
|
| Organizational Policy | 2 | 2016 | 12 | 0.040 |
Why?
|
| Psychotherapy | 1 | 2021 | 56 | 0.040 |
Why?
|
| Nursing Evaluation Research | 1 | 2020 | 3 | 0.040 |
Why?
|
| Animals | 1 | 2021 | 280 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 58 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2021 | 92 | 0.040 |
Why?
|
| Chronic Disease | 3 | 2016 | 397 | 0.040 |
Why?
|
| Government Programs | 1 | 2020 | 12 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 287 | 0.040 |
Why?
|
| Bibliometrics | 1 | 2020 | 3 | 0.040 |
Why?
|
| Multimorbidity | 1 | 2020 | 12 | 0.040 |
Why?
|
| Protective Factors | 1 | 2020 | 32 | 0.040 |
Why?
|
| Job Satisfaction | 1 | 2000 | 20 | 0.040 |
Why?
|
| Unnecessary Procedures | 1 | 2000 | 21 | 0.040 |
Why?
|
| Incidence | 2 | 2019 | 1266 | 0.040 |
Why?
|
| Gynecology | 1 | 2000 | 22 | 0.040 |
Why?
|
| Education, Medical | 2 | 1996 | 16 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 191 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 65 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2011 | 535 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2020 | 163 | 0.040 |
Why?
|
| Viral Load | 1 | 2020 | 136 | 0.040 |
Why?
|
| Self Report | 1 | 2021 | 257 | 0.040 |
Why?
|
| Depressive Disorder | 1 | 2001 | 185 | 0.040 |
Why?
|
| Oregon | 1 | 2019 | 170 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2007 | 357 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 146 | 0.040 |
Why?
|
| European Continental Ancestry Group | 1 | 2021 | 476 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2020 | 134 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2016 | 1226 | 0.040 |
Why?
|
| Washington | 1 | 2019 | 384 | 0.040 |
Why?
|
| Age Factors | 2 | 2015 | 878 | 0.040 |
Why?
|
| Rorschach Test | 1 | 1978 | 1 | 0.040 |
Why?
|
| Reminder Systems | 2 | 2013 | 74 | 0.040 |
Why?
|
| Reimbursement, Incentive | 2 | 2012 | 21 | 0.040 |
Why?
|
| Data Collection | 2 | 2015 | 238 | 0.040 |
Why?
|
| Sex Factors | 2 | 2015 | 603 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 674 | 0.040 |
Why?
|
| Stakeholder Participation | 1 | 2018 | 21 | 0.040 |
Why?
|
| Group Practice, Prepaid | 1 | 1997 | 6 | 0.030 |
Why?
|
| Independent Practice Associations | 1 | 1997 | 5 | 0.030 |
Why?
|
| Cataract Extraction | 1 | 1997 | 2 | 0.030 |
Why?
|
| Fee-for-Service Plans | 1 | 1997 | 21 | 0.030 |
Why?
|
| Oncologists | 1 | 2016 | 7 | 0.030 |
Why?
|
| Culture | 1 | 2016 | 30 | 0.030 |
Why?
|
| Clinical Medicine | 1 | 1996 | 4 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 8 | 0.030 |
Why?
|
| Monitoring, Ambulatory | 1 | 2016 | 18 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2016 | 41 | 0.030 |
Why?
|
| Sleep Wake Disorders | 1 | 2016 | 34 | 0.030 |
Why?
|
| Exercise | 1 | 2021 | 515 | 0.030 |
Why?
|
| Practice Management, Medical | 1 | 1995 | 7 | 0.030 |
Why?
|
| Group Practice | 1 | 1995 | 21 | 0.030 |
Why?
|
| Adolescent | 2 | 2021 | 3538 | 0.030 |
Why?
|
| Medication Reconciliation | 1 | 2015 | 6 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 338 | 0.030 |
Why?
|
| Senior Centers | 1 | 2015 | 2 | 0.030 |
Why?
|
| Korea | 1 | 2015 | 9 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 1076 | 0.030 |
Why?
|
| Anxiety | 1 | 2016 | 154 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2015 | 12 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 1996 | 86 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2015 | 68 | 0.030 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 1995 | 6 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 252 | 0.030 |
Why?
|
| Software | 1 | 1995 | 19 | 0.030 |
Why?
|
| Mental Disorders | 1 | 1978 | 274 | 0.030 |
Why?
|
| Safe Sex | 1 | 2014 | 4 | 0.030 |
Why?
|
| Condoms | 1 | 2014 | 33 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 163 | 0.030 |
Why?
|
| Young Adult | 1 | 2021 | 2465 | 0.030 |
Why?
|
| Continental Population Groups | 1 | 2016 | 286 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 63 | 0.030 |
Why?
|
| Managed Care Programs | 1 | 1995 | 300 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2004 | 298 | 0.030 |
Why?
|
| Family Health | 1 | 2013 | 45 | 0.030 |
Why?
|
| Social Conformity | 1 | 1992 | 1 | 0.030 |
Why?
|
| District of Columbia | 1 | 1992 | 17 | 0.020 |
Why?
|
| Ethnic Groups | 1 | 2016 | 451 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2014 | 260 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2011 | 41 | 0.020 |
Why?
|
| Hospitalization | 1 | 2017 | 804 | 0.020 |
Why?
|
| Linear Models | 2 | 2003 | 206 | 0.020 |
Why?
|
| Motivation | 2 | 2004 | 115 | 0.020 |
Why?
|
| Regression Analysis | 2 | 2002 | 270 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2007 | 45 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2006 | 59 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2006 | 66 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 622 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 605 | 0.020 |
Why?
|
| Range of Motion, Articular | 1 | 2004 | 2 | 0.010 |
Why?
|
| Defensive Medicine | 1 | 2004 | 3 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2003 | 26 | 0.010 |
Why?
|
| Patient Participation | 1 | 2004 | 119 | 0.010 |
Why?
|
| Virginia | 1 | 2003 | 5 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2003 | 121 | 0.010 |
Why?
|
| Organizational Culture | 1 | 2003 | 15 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2004 | 342 | 0.010 |
Why?
|
| Expert Testimony | 1 | 2002 | 5 | 0.010 |
Why?
|
| Mass Media | 1 | 2002 | 15 | 0.010 |
Why?
|
| Feedback | 1 | 2002 | 20 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2004 | 640 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2001 | 82 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2001 | 139 | 0.010 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2001 | 9 | 0.010 |
Why?
|
| Gender Identity | 1 | 2001 | 33 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2001 | 45 | 0.010 |
Why?
|
| Random Allocation | 1 | 2000 | 33 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 2001 | 128 | 0.010 |
Why?
|
| MMPI | 1 | 1978 | 1 | 0.010 |
Why?
|
| Social Desirability | 1 | 1978 | 1 | 0.010 |
Why?
|
| Schizophrenia | 1 | 1978 | 76 | 0.010 |
Why?
|
| Physicians, Family | 1 | 1997 | 36 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 1997 | 45 | 0.010 |
Why?
|
| Sex Distribution | 1 | 1997 | 180 | 0.010 |
Why?
|
| Physician Executives | 1 | 1996 | 4 | 0.010 |
Why?
|
| Age Distribution | 1 | 1997 | 239 | 0.010 |
Why?
|
| Quality Control | 1 | 1996 | 41 | 0.010 |
Why?
|
| Preventive Medicine | 1 | 1996 | 22 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 1996 | 3 | 0.010 |
Why?
|
| Decision Trees | 1 | 1996 | 18 | 0.010 |
Why?
|
| Insurance, Health | 1 | 1997 | 170 | 0.010 |
Why?
|
| Models, Statistical | 1 | 1996 | 170 | 0.010 |
Why?
|
| Computer-Assisted Instruction | 1 | 1995 | 10 | 0.010 |
Why?
|
| User-Computer Interface | 1 | 1995 | 21 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 1994 | 15 | 0.010 |
Why?
|
| Depression | 1 | 1978 | 486 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 1997 | 452 | 0.010 |
Why?
|